Peptides · Peptide comparison
Lactoferricin B vs Thymosin Alpha-1
A 25-amino-acid antimicrobial peptide fragment derived from bovine lactoferrin by pepsin cleavage, featuring a twisted antiparallel beta-sheet structure with broad-spectrum bactericidal activity, anti-biofilm properties, and emerging anticancer potential through selective membrane disruption mediated by the critical RRWQWR motif
Your immune system's master trainer—a naturally occurring thymus peptide that wakes up tired immune cells, helps your body fight infections, and keeps your defenses sharp as you age.
- Immune
- Immune
At a glance
Quick comparison
Efficacy
Benefit ratings
Fighting Germs
Cancer Cell Targeting
Immune Support
Immune Activation
Infection Fighting
Immune Balance
Technical data
Compound specifications
Lactoferricin B
- Molecular formula
- Approximately C142H224N46O34S2 (varies slightly by reported sequence)
- Molecular weight
- ~3,126 Da (25-amino-acid bovine lactoferricin B)
- Half-life
- Plasma half-life: minutes (proteolytic degradation); gastrointestinal persistence: hours (relative resistance to trypsin and chymotrypsin compared to unstructured peptides); beta-sheet structure and disulfide bond provide moderate protease resistance
- Bioavailability
- Generated endogenously during gastric digestion of dietary lactoferrin; partially resistant to further proteolytic degradation due to beta-sheet structure and disulfide bond; systemic bioavailability limited by intestinal proteases and hepatic metabolism
- CAS number
- 146897-68-9
Thymosin Alpha-1
- Molecular formula
- C129H215N33O55
- Molecular weight
- 3108.32 g/mol
- Half-life
- Approximately 2 hours
- Bioavailability
- High when injected subcutaneously (rapid absorption, peak at ~2 hours)
- CAS number
- 62304-98-7
Protocols
Dosing compared
Lactoferricin B
No dose levels recorded.
Thymosin Alpha-1
Subcutaneous injection
- 1.6 mgTwice weekly (3-4 days apart) · 6-12 monthsEstablished clinical dose for thymalfasin (Zadaxin); body-surface-scaled as 900 mcg/m2 [4][6]. Phase III chronic hepatitis B trials used 1.6 mg SC twice weekly for 6-12 months [4].
- 1.6 mg daily, then 1.6 mg twice weeklyDaily for an initial loading period, then twice weekly · 12+ weeksThe schedule used in a randomized trial in HBV-related acute-on-chronic liver failure: 1.6 mg daily for the first week, then twice weekly to week 12 [3].
Applications
Best suited for
Lactoferricin B
- Research into dairy-derived antimicrobial peptides and natural innate defense mechanisms
- Lactoferricin B is particularly well-suited for individuals focused on research into dairy-derived antimicrobial peptides and natural innate defense mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Investigation of structure-activity relationships in beta-sheet antimicrobial peptides
- Lactoferricin B is particularly well-suited for individuals focused on investigation of structure-activity relationships in beta-sheet antimicrobial peptides. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Preclinical development of anticancer peptides targeting membrane phospholipid asymmetry
- Lactoferricin B is particularly well-suited for individuals focused on preclinical development of anticancer peptides targeting membrane phospholipid asymmetry. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion
- Lactoferricin B is particularly well-suited for individuals focused on understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Thymosin Alpha-1
- Chronic Hepatitis B or C Support
- Thymosin Alpha-1 has its strongest clinical evidence here. Multiple trials show it helps clear viral loads and normalize liver enzymes, especially when combined with antiviral medications. It's approved in over 30 countries specifically for hepatitis treatment.
- Cancer Treatment Support
- When used alongside chemotherapy, Thymosin Alpha-1 may help maintain immune function that chemo tends to suppress. Research in lung cancer, melanoma, and liver cancer shows improved outcomes when added to standard treatments. It helps your immune system keep fighting even during tough treatments.
- Age-Related Immune Decline
- As you age, your thymus shrinks and produces less thymosin naturally—a process called immunosenescence. Supplementing with Thymosin Alpha-1 may help compensate, keeping your immune defenses more youthful and responsive. Think of it as replacing what your body makes less of over time.
- Severe Infection Recovery
- In sepsis and critical infections, Thymosin Alpha-1 has shown promise for reducing mortality by helping restore immune balance. It's particularly interesting because it modulates immunity rather than just boosting it—calming overreaction while enhancing pathogen-fighting ability.
Safety profile
Side effects
Lactoferricin B
Common
- Mild GI discomfort
- Bitter taste
- Local irritation (topical use)
- Mild flatulence
Uncommon
- Allergic reaction in milk-sensitive individuals
Serious
- Hemolytic activity at high concentrations
Thymosin Alpha-1
Common
- Injection site reactions
Uncommon
- Mild fatigue
- Flu-like symptoms
- Mild fever
- Lymph node awareness
Serious
- Allergic reaction
Research status
Safety & evidence
Lactoferricin B
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Research compound
- Safety overview
- Lactoferricin B is a 25-amino acid peptide fragment of bovine lactoferrin, a protein found in cow's milk [2]. Preclinical studies show excellent tolerability with no hepatotoxicity, nephrotoxicity, or genotoxicity in animal models even at supraphysiological doses. The antimicrobial and antifungal mechanism (iron sequestration and membrane disruption) appears selective for pathogenic microorganisms with minimal effect on commensal bacteria at therapeutic concentrations.
Contraindications
- Known allergy to bovine milk proteins or lactoferrin — cross-reactivity possible
- Pregnancy and breastfeeding — insufficient safety data for therapeutic-dose lactoferricin supplementation
- Active hemolytic conditions — at higher concentrations lactoferricin shows some hemolytic activity that may worsen hemolysis
- Iron overload conditions (hemochromatosis) — lactoferricin retains some iron-binding capacity from the parent lactoferrin molecule
Thymosin Alpha-1
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Not FDA approved. There is no thymalfasin application in Drugs@FDA. It is used outside the US (as Zadaxin) for chronic hepatitis B and as an immune adjuvant.
- Safety overview
- Thymosin Alpha-1 has one of the most extensive safety records of any peptide, with decades of clinical use across multiple countries. Studies consistently report minimal side effects—mostly limited to mild injection site reactions. The 2-hour half-life means it doesn't accumulate in your system. It's been used safely in thousands of patients with hepatitis, cancer, and other serious conditions.
Contraindications
- Organ transplant recipients on immunosuppressants
- Active autoimmune disease flares
- Known allergy to thymosin peptides
- Pregnancy or breastfeeding
- Children under 18 without medical supervision
Decision guide
Which is right for you?
Lactoferricin B
Choose Lactoferricin B if…
- Research into dairy-derived antimicrobial peptides and natural innate defense mechanisms
- Investigation of structure-activity relationships in beta-sheet antimicrobial peptides
- Preclinical development of anticancer peptides targeting membrane phospholipid asymmetry
- Understanding the gastrointestinal antimicrobial defense provided by dietary lactoferrin digestion
Thymosin Alpha-1
Choose Thymosin Alpha-1 if…
- Immune system strengthening
- Chronic infection support
- Cancer adjunct therapy
- Healthy aging immune support